- We have one of the largest vaccine portfolios in the world: Ebrard.
- In June, Mexico will have received a total of 65 million doses.
- The AstraZeneca vaccine will supply not only Mexico and Argentina, but also 17 additional countries in Latin America and the Caribbean that have contracts with the UK pharmaceutical company.
During this morning's press conference headed by President Andrés Manuel López Obrador, Foreign Secretary Marcelo Ebrard reported that as of this week - as planned - Mexico has received a total of 40 million doses of various Covid-19 vaccines. By the end of June, that total will rise to 65 million doses.
This will accelerate the National Vaccination Plan and is sufficient to cover the different age groups that are waiting to be immunized. The Foreign Secretary said that one of the main reasons why Mexico has this large supply is because of its range of options, stemming from the various sources to which the country has access. "We have one of the largest vaccine portfolios in the world, and that has helped us a lot,” he said.
The Secretary added that the Janssen vaccine from the U.S. Johnson & Johnson pharmaceutical company has been approved by the Federal Commission for Protection against Health Risks (Cofepris), and would be added to Mexico's options for its National Vaccination Strategy.
Foreign Secretary Ebrard said that another reason why Mexico will be able to accelerate its vaccination rate is the successful production of the AstraZeneca vaccine in Latin America, specifically Mexico's part in fill-finishing the active ingredient. The first batches of the vaccine will be released this week.
The Foreign Secretary underscored Mexico's collaboration with Argentina on the AstraZeneca vaccine production chain for the region, saying that it would not have been possible without the cooperation agreement spearheaded by President Andrés Manuel López Obrador and Argentinian President Alberto Fernández in recent months. The vaccine will not only supply Mexico and Argentina, but also 17 additional countries in Latin America and the Caribbean that have contracts with the United Kingdom pharmaceutical company.
The Ministry of Foreign Affairs reaffirms its commitment to conduct a foreign policy that prioritizes the health of the Mexican people, and contributes to universal, timely and equitable access to the COVID-19 vaccine.
